The inclusion of a non-cancer control group in comparison with SCBT, and the similar results noted between groups provides confidence in the results and indicate that leptin is a useful adiposity biomarker in SCBT.  The determination that leptin is a predictor of total and central adiposity in SCBT is novel and provides a baseline for future studies of adiposity in this population. Here, LEP is linked to cancer.